Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Abstract	More than 50 years of research has yielded numerous Shigella vaccine candidates that have exemplified both the promise of vaccine-induced prevention of shigellosis and the impediments to developing a safe and effective vaccine for widespread use, a goal that has yet to be attained. This Review discusses the most advanced strategies for Shigella vaccine development, the immune responses that are elicited following disease or vaccination, the factors that have accelerated or impeded Shigella vaccine development and our ideas for the way forward.
Authors	Myron M Levine, Karen L Kotloff, Eileen M Barry, Marcela F Pasetti, Marcelo B Sztein
Journal	Nature reviews. Microbiology (Nat Rev Microbiol) Vol. 5 Issue 7 Pg. 540-53 (Jul 2007) ISSN: 1740-1534 [Electronic] England
PMID	17558427 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)
Chemical References	Antibodies, Bacterial Shigella Vaccines Vaccines, Attenuated
Topics	Antibodies, Bacterial (blood) Child, Preschool Clinical Trials as Topic Dysentery, Bacillary (epidemiology, immunology, microbiology, prevention & control) Humans Immunity, Cellular Infant Shigella (classification, immunology) Shigella Vaccines (administration & dosage, adverse effects, immunology) Vaccination Vaccines, Attenuated (administration & dosage, adverse effects, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!